Sheena Jonathan, a co-founder of Natera, Inc. (NASDAQ:NTRA), disposed of $365,914 worth of the company’s stock on January 23, 2026, executing the sales under a pre-arranged trading plan. The transactions spanned multiple tranches, with executed prices ranging from $242.232 to $245.62 per share.
The shares sold were held in two family trusts. Details by trust and price band are as follows:
- Caraluna 1 Trust: 160 shares sold at a weighted average price of $242.3113; 185 shares at $243.4905; 355 shares at $244.7804; and 50 shares at $245.62.
- Caraluna 2 Trust: 200 shares sold at a weighted average price of $242.2320; 160 shares at $243.5872; and 390 shares at $244.8726.
After these transactions, Jonathan directly holds 264078 shares of Natera. The trusts hold identical positions following the sales, with Caraluna 1 Trust holding 21782 shares and Caraluna 2 Trust holding 21782 shares.
In separate company developments, Natera released preliminary fourth-quarter 2025 results that management characterizes as strong. The company expects revenue to have increased nearly 40% year-over-year for the quarter, a pace that the preliminary figures indicate topped analyst expectations. Test volume for the period is reported to have risen by approximately 17%.
Reflecting those results, Canaccord Genuity has maintained a Buy rating on Natera and set a price target of $285.00.
Natera also announced a strategic collaboration with Exelixis Inc. to support a pivotal phase 3 clinical trial in colorectal cancer patients. The trial will use Natera’s Signatera test to identify patients exhibiting molecular residual disease for enrollment in the study.
On the technology front, Natera introduced a new multi-modal artificial intelligence model designed to improve cancer recurrence risk assessment by enhancing molecular residual disease (MRD) measurement. The model is intended to combine multiple data types, including circulating tumor DNA and digital pathology imaging.
Additional scientific validation for Signatera was noted: the test was used in a study published in JAMA Oncology that reported improved survival for certain colorectal cancer patients treated with celecoxib. Meanwhile, Natera is scheduled to present data from its EXPAND clinical trial on fetal genetic screening at the Society for Maternal-Fetal Medicine meeting in February 2026.
The reported insider sales, the company’s preliminary financial results, plus its clinical and AI initiatives present a multifaceted view of Natera’s current activity. The share disposals occurred under a pre-arranged plan and were executed across two family trusts, while the company continues to disclose forward-looking clinical programs and early financial metrics for fourth-quarter 2025.